See more : Toray Industries, Inc. (TRYIY) Income Statement Analysis – Financial Results
Complete financial analysis of Innovent Biologics, Inc. (IVBXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innovent Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Xerox Holdings Corporation (XRX) Income Statement Analysis – Financial Results
- Hunan Friendship&Apollo Commercial Co.,Ltd. (002277.SZ) Income Statement Analysis – Financial Results
- Zacatecas Silver Corp. (ZCTSF) Income Statement Analysis – Financial Results
- The Lovesac Company (LOVE) Income Statement Analysis – Financial Results
- Sangam (India) Limited (SANGAMIND.BO) Income Statement Analysis – Financial Results
Innovent Biologics, Inc. (IVBXF)
About Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.21B | 4.56B | 4.27B | 3.84B | 1.05B | 9.48M | 18.54M | 32.13M |
| Cost of Revenue | 1.81B | 930.99M | 573.04M | 387.76M | 124.88M | -1.31M | -71.47M | 0.00 |
| Gross Profit | 4.40B | 3.63B | 3.70B | 3.46B | 922.65M | 10.79M | 90.01M | 32.13M |
| Gross Profit Ratio | 70.89% | 79.57% | 86.58% | 89.91% | 88.08% | 113.84% | 485.54% | 100.00% |
| Research & Development | 2.23B | 2.87B | 2.48B | 1.85B | 1.29B | 1.22B | 611.92M | 384.65M |
| General & Administrative | 750.28M | 835.49M | 884.03M | 436.87M | 255.30M | 277.50M | 87.77M | 57.38M |
| Selling & Marketing | 3.10B | 2.59B | 2.73B | 1.34B | 1.19B | 136.01M | 9.94M | 5.03M |
| SG&A | 3.85B | 3.43B | 3.61B | 1.78B | 1.45B | 413.51M | 87.77M | 57.38M |
| Other Expenses | 0.00 | -90.20M | -45.13M | -130.69M | -41.38M | -4.34B | -51.01M | -123.20M |
| Operating Expenses | 5.07B | 6.21B | 6.05B | 3.50B | 2.70B | 1.56B | 643.27M | 413.27M |
| Cost & Expenses | 7.89B | 7.14B | 6.62B | 3.89B | 2.83B | 1.56B | 643.27M | 413.27M |
| Interest Income | 452.84M | 189.54M | 151.76M | 116.10M | 102.70M | 20.68M | 7.98M | 4.54M |
| Interest Expense | 98.62M | 101.70M | 62.46M | 68.35M | 59.49M | 68.97M | 57.23M | 53.80M |
| Depreciation & Amortization | 385.10M | 319.42M | 204.75M | 85.63M | 86.37M | 64.06M | 61.10M | 53.35M |
| EBITDA | -660.68M | -1.75B | -2.37B | -704.74M | -1.57B | -5.74B | -597.72M | -359.92M |
| EBITDA Ratio | -10.65% | -38.51% | -68.11% | -19.11% | -150.52% | -60,586.43% | -3,430.40% | -1,413.33% |
| Operating Income | -1.68B | -2.07B | -3.11B | -820.14M | -1.66B | -1.79B | -750.14M | -461.54M |
| Operating Income Ratio | -27.06% | -45.52% | -72.91% | -21.34% | -158.76% | -18,841.75% | -4,046.48% | -1,436.60% |
| Total Other Income/Expenses | 534.89M | -96.54M | 61.63M | -301.53M | -56.86M | -4.32B | -91.32M | -131.19M |
| Income Before Tax | -1.14B | -2.17B | -3.05B | -858.71M | -1.72B | -5.87B | -716.05M | -544.46M |
| Income Before Tax Ratio | -18.44% | -47.64% | -71.46% | -22.34% | -164.19% | -61,970.90% | -3,862.61% | -1,694.69% |
| Income Tax Expense | -116.50M | 8.80M | 87.04M | 139.71M | 56.86M | 27.48M | -244.37M | -150.97M |
| Net Income | -1.03B | -2.18B | -3.14B | -998.42M | -1.78B | -5.77B | -562.32M | -504.20M |
| Net Income Ratio | -16.56% | -47.83% | -73.50% | -25.97% | -169.62% | -60,899.99% | -3,033.33% | -1,569.40% |
| EPS | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| EPS Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| Weighted Avg Shares Out | 1.56B | 1.49B | 1.45B | 1.35B | 1.18B | 334.68M | 1.12B | 1.12B |
| Weighted Avg Shares Out (Dil) | 1.56B | 1.49B | 1.46B | 1.36B | 1.18B | 334.68M | 1.12B | 1.12B |
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology
Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day
Source: https://incomestatements.info
Category: Stock Reports